<!DOCTYPE html>
<html lang="zh-CN">
<head>
    <meta charset="UTF-8">
    <meta name="viewport" content="width=device-width, initial-scale=1.0, maximum-scale=5.0">
    <title>ç§‘ç ”æ—¥æŠ¥ - 2026-02-19</title>
    <style>
        * {
            margin: 0;
            padding: 0;
            box-sizing: border-box;
        }

        body {
            font-family: -apple-system, BlinkMacSystemFont, "Segoe UI", Roboto, "Helvetica Neue", Arial, "Noto Sans", sans-serif, "Apple Color Emoji", "Segoe UI Emoji";
            line-height: 1.8;
            color: #2c3e50;
            background: linear-gradient(135deg, #f5f7fa 0%, #c3cfe2 100%);
            padding: 15px;
            font-size: 16px;
        }

        .container {
            max-width: 900px;
            margin: 0 auto;
            background: white;
            padding: 35px;
            border-radius: 16px;
            box-shadow: 0 10px 40px rgba(0,0,0,0.1);
        }

        /* æ ‡é¢˜ä¼˜åŒ– */
        h1 {
            color: #1a202c;
            font-size: 2em;
            border-bottom: 4px solid #667eea;
            padding-bottom: 15px;
            margin-bottom: 25px;
            font-weight: 700;
            background: linear-gradient(135deg, #667eea 0%, #764ba2 100%);
            -webkit-background-clip: text;
            -webkit-text-fill-color: transparent;
            background-clip: text;
        }

        h2 {
            color: #2d3748;
            font-size: 1.5em;
            margin-top: 40px;
            margin-bottom: 20px;
            padding-left: 15px;
            border-left: 5px solid #667eea;
            font-weight: 600;
        }

        h3 {
            color: #4a5568;
            font-size: 1.25em;
            margin-top: 28px;
            margin-bottom: 14px;
            font-weight: 600;
        }

        /* åˆ†ç±»æµè§ˆæŠ˜å åŠŸèƒ½ */
        details {
            margin: 20px 0;
            border-radius: 8px;
            overflow: hidden;
        }

        details summary {
            cursor: pointer;
            padding: 15px 20px;
            background: linear-gradient(135deg, #f8f9fa 0%, #e9ecef 100%);
            color: #2d3748;
            font-size: 1.25em;
            font-weight: 600;
            text-align: right;
            direction: rtl;
            border-right: 5px solid #667eea;
            transition: all 0.3s ease;
            list-style: none;
            user-select: none;
        }

        details summary * {
            direction: ltr;
        }

        details summary::-webkit-details-marker {
            display: none;
        }

        details summary::before {
            content: 'â–¶';
            display: inline-block;
            margin-left: 10px;
            transition: transform 0.3s ease;
            font-size: 0.8em;
        }

        details[open] summary::before {
            transform: rotate(90deg);
        }

        details summary:hover {
            background: linear-gradient(135deg, #667eea 0%, #764ba2 100%);
            color: white;
            box-shadow: 0 4px 12px rgba(102, 126, 234, 0.3);
        }

        details[open] summary {
            background: linear-gradient(135deg, #667eea 0%, #764ba2 100%);
            color: white;
            border-right-color: white;
        }

        details .details-content {
            padding: 20px;
            background: white;
            border: 1px solid #e9ecef;
            border-top: none;
        }

        h4 {
            color: #718096;
            font-size: 1.1em;
            margin-top: 22px;
            margin-bottom: 12px;
            font-weight: 600;
        }

        p {
            margin-bottom: 16px;
            line-height: 1.8;
        }

        blockquote {
            background: linear-gradient(135deg, #f8f9fa 0%, #e9ecef 100%);
            border-left: 4px solid #667eea;
            padding: 18px 22px;
            margin: 22px 0;
            border-radius: 8px;
            color: #4a5568;
            font-size: 0.95em;
            box-shadow: 0 2px 8px rgba(0,0,0,0.05);
        }

        blockquote p {
            margin-bottom: 8px;
        }

        blockquote p:last-child {
            margin-bottom: 0;
        }

        blockquote em {
            font-style: normal;
            color: #718096;
            font-size: 0.9em;
        }

        blockquote a {
            color: #667eea;
            font-weight: 500;
            border-bottom: 1px solid rgba(102, 126, 234, 0.3);
        }

        blockquote a:hover {
            color: #764ba2;
            border-bottom-color: #764ba2;
        }

        /* é¡¶éƒ¨ç½²åï¼ˆå±…å³ï¼‰ */
        .powered-by-top {
            text-align: right;
            font-size: 0.85em;
            color: #718096;
            font-style: italic;
            margin: 12px 0;
            padding-right: 5px;
        }

        .powered-by-top a {
            color: #667eea;
            font-weight: 500;
            border-bottom: 1px solid rgba(102, 126, 234, 0.3);
        }

        .powered-by-top a:hover {
            color: #764ba2;
            border-bottom-color: #764ba2;
        }

        /* AI æ€»ç»“åŒºåŸŸä¼˜åŒ– */
        .ai-summary {
            background: linear-gradient(135deg, #667eea 0%, #764ba2 100%);
            color: white;
            padding: 28px;
            border-radius: 16px;
            margin: 30px 0;
            box-shadow: 0 12px 35px rgba(102, 126, 234, 0.35);
            position: relative;
            overflow: hidden;
        }

        .ai-summary::before {
            content: '';
            position: absolute;
            top: -50%;
            right: -50%;
            width: 200%;
            height: 200%;
            background: radial-gradient(circle, rgba(255,255,255,0.1) 0%, transparent 70%);
            pointer-events: none;
        }

        .ai-summary h2 {
            color: white;
            border-left: none;
            border-right: none;
            margin-top: 0;
            margin-bottom: 18px;
            padding-left: 15px;
            padding-right: 0;
            text-align: left;
            direction: ltr;
        }

        .ai-summary h3 {
            color: #f0f0f0;
            margin-top: 18px;
            border-right: 3px solid rgba(255,255,255,0.5);
            padding-right: 12px;
            padding-left: 0;
            text-align: right;
            direction: rtl;
        }

        .ai-summary h3 * {
            direction: ltr;
        }

        .ai-summary blockquote {
            background: rgba(255,255,255,0.15);
            border-left-color: white;
            color: white;
            backdrop-filter: blur(10px);
        }

        .ai-summary p {
            color: white;
        }

        .ai-summary strong {
            color: #fff;
            font-weight: 600;
        }

        ul, ol {
            margin-left: 28px;
            margin-bottom: 18px;
        }

        li {
            margin-bottom: 12px;
            line-height: 1.8;
        }

        /* é“¾æ¥ä¼˜åŒ– */
        a {
            color: #667eea;
            text-decoration: none;
            border-bottom: 1px solid transparent;
            transition: all 0.3s ease;
            font-weight: 500;
        }

        a:hover {
            border-bottom-color: #667eea;
            color: #764ba2;
        }

        /* è¡¨æ ¼ä¼˜åŒ– */
        table {
            width: 100%;
            border-collapse: collapse;
            margin: 20px 0;
            box-shadow: 0 2px 12px rgba(0,0,0,0.08);
            border-radius: 10px;
            overflow: hidden;
        }

        th, td {
            border: 1px solid #e2e8f0;
            padding: 14px 18px;
            text-align: left;
        }

        th {
            background: linear-gradient(135deg, #667eea 0%, #764ba2 100%);
            color: white;
            font-weight: 600;
            font-size: 0.95em;
        }

        tr:nth-child(even) {
            background: #f8f9fa;
        }

        tr:hover {
            background: #e9ecef;
            transition: background 0.3s ease;
        }

        /* å…³é”®è¯ç»Ÿè®¡è¡¨æ ¼ç‰¹æ®Šæ ·å¼ï¼ˆæ›´ç´§å‡‘ï¼‰ */
        .keywords-table {
            font-size: 0.9em;
            max-width: 600px;
        }

        .keywords-table th,
        .keywords-table td {
            padding: 10px 14px;
        }

        .keywords-table th {
            font-size: 0.9em;
        }

        hr {
            border: none;
            border-top: 2px solid #e2e8f0;
            margin: 40px 0;
        }

        strong {
            color: #2d3748;
            font-weight: 600;
        }

        code {
            background: #f1f5f9;
            padding: 3px 8px;
            border-radius: 5px;
            font-family: "SF Mono", Monaco, Consolas, "Courier New", monospace;
            font-size: 0.9em;
            color: #e53e3e;
        }

        /* ç¾åŒ–æ»šåŠ¨æ¡ */
        ::-webkit-scrollbar {
            width: 8px;
            height: 8px;
        }

        ::-webkit-scrollbar-track {
            background: #f1f1f1;
            border-radius: 4px;
        }

        ::-webkit-scrollbar-thumb {
            background: #667eea;
            border-radius: 4px;
        }

        ::-webkit-scrollbar-thumb:hover {
            background: #764ba2;
        }

        /* ç§»åŠ¨ç«¯ä¼˜åŒ– */
        @media (max-width: 768px) {
            body {
                padding: 8px;
                font-size: 15px;
            }

            .container {
                padding: 22px 18px;
                border-radius: 12px;
            }

            h1 {
                font-size: 1.6em;
                padding-bottom: 12px;
                margin-bottom: 20px;
            }

            h2 {
                font-size: 1.3em;
                margin-top: 30px;
                padding-left: 12px;
            }

            h3 {
                font-size: 1.15em;
            }

            h4 {
                font-size: 1.05em;
            }

            blockquote {
                padding: 14px 16px;
                margin: 18px 0;
            }

            .ai-summary {
                padding: 20px;
                margin: 22px 0;
            }

            .ai-summary-header {
                flex-direction: column;
                align-items: flex-start;
            }

            .powered-by {
                margin-left: 0;
                margin-top: 8px;
            }

            table {
                font-size: 0.85em;
            }

            th, td {
                padding: 10px 12px;
            }

            .keywords-table {
                font-size: 0.8em;
            }

            .keywords-table th,
            .keywords-table td {
                padding: 8px 10px;
            }

            ul, ol {
                margin-left: 22px;
            }
        }

        /* è¶…å°å±å¹• */
        @media (max-width: 480px) {
            body {
                font-size: 14px;
                padding: 5px;
            }

            .container {
                padding: 18px 14px;
            }

            h1 {
                font-size: 1.4em;
            }

            h2 {
                font-size: 1.2em;
            }

            .ai-summary {
                padding: 16px;
            }

            .powered-by {
                font-size: 0.7em;
            }
        }

        /* å¹³æ»‘æ»šåŠ¨ */
        html {
            scroll-behavior: smooth;
        }

        /* æé«˜å¯ç‚¹å‡»åŒºåŸŸ */
        @media (pointer: coarse) {
            a {
                padding: 4px 0;
                display: inline-block;
            }
        }

        /* æ‰“å°ä¼˜åŒ– */
        @media print {
            body {
                background: white;
                padding: 0;
            }

            .container {
                box-shadow: none;
                max-width: 100%;
            }

            .ai-summary {
                background: #f5f5f5;
                color: black;
                box-shadow: none;
            }

            .ai-summary h2,
            .ai-summary h3,
            .ai-summary p,
            .ai-summary strong {
                color: black;
            }
        }
    </style>
</head>
<body>
    <div class="container">
        <h1>ğŸ“… Daily Report - 2026-02-19</h1>
<blockquote>
<p>ä»Šæ—¥ç­›é€‰å‡º <strong>60</strong> æ¡å†…å®¹ï¼Œæ¥è‡ª <strong>2</strong> ä¸ªæ¥æº</p>
</blockquote>
<div class="powered-by-top">Powered by <a href="https://kyplus.de" target="_blank" rel="noopener noreferrer">ç§‘ç ”æ™®æ‹‰æ–¯</a> & <a href="https://claude.ai" target="_blank" rel="noopener noreferrer">Claude</a></div>

<hr />
<div class="ai-summary">
                <h2>ğŸ¤– ä»Šæ—¥AIæ™ºèƒ½æ€»ç»“</h2>
                <h3>ğŸ§¬ æ•°æ®å‰æ²¿</h3>
<blockquote>
<p><strong>ä»Šæ—¥ç„¦ç‚¹</strong>ï¼š<br />
ç©ºé—´è½¬å½•ç»„å­¦æŠ€æœ¯åœ¨è‚¿ç˜¤å¾®ç¯å¢ƒç ”ç©¶ä¸­å–å¾—çªç ´ï¼Œæ­ç¤ºäº†èƒƒç™Œäºšå‹ã€é»‘è‰²ç´ ç˜¤åŠèƒ°è…ºç™Œçš„å…ç–«å¼‚è´¨æ€§ï¼Œå¹¶é¦–æ¬¡å®ç°äº†å¯¹åŸå‘åŠè½¬ç§»è‚¿ç˜¤ç»“æ„çš„åŸä½é‡å»ºã€‚</p>
</blockquote>
<p><strong>ä¸»è¦æ–¹å‘</strong>ï¼š<br />
- è‚¿ç˜¤å¾®ç¯å¢ƒï¼šåˆ†æèƒƒç™Œã€èƒ°è…ºç™Œã€åµå·¢ç™Œã€é»‘è‰²ç´ ç˜¤å’Œç»“ç›´è‚ ç™Œçš„å…ç–«ç»†èƒæ„æˆã€åŸºå› è¡¨è¾¾æ”¹å˜åŠå¯¹æ²»ç–—çš„å“åº”ã€‚<br />
- åŸºå› ç»„ä¸è¡¨è§‚é—ä¼ å­¦ï¼šç ”ç©¶DNAç”²åŸºåŒ–åœ¨é¸¡èƒšè‚è„è‚Œè‚‰åŠäº¨å»·é¡¿èˆè¹ˆç—…ä¸­çš„ä½œç”¨ï¼Œä»¥åŠSetdb1ä»‹å¯¼çš„XæŸ“è‰²ä½“æ²‰é»˜æœºåˆ¶ã€‚<br />
- ç¥ç»ç§‘å­¦ï¼šå¼€å‘æ–°å‹ç—…æ¯’å·¥å…·ç”¨äºå¤§è§„æ¨¡ç¥ç»å›è·¯å›¾è°±ç»˜åˆ¶ï¼Œå¹¶æ¢ç´¢ç¼ºæ°§æ¡ä»¶ä¸‹NKç»†èƒçš„è½¬å½•è°ƒæ§ã€‚</p>
<p><strong>æŠ€æœ¯äº®ç‚¹</strong>ï¼š<br />
- GISå¢å¼ºçš„ç©ºé—´è½¬å½•ç»„å­¦ï¼šå®ç°å¯¹åŸå‘åŠè½¬ç§»è‚¿ç˜¤ç»“æ„çš„ in silico é‡å»ºã€‚<br />
- æŠ—ä½“æ ‡è®°ç»“åˆæµå¼ç»†èƒæœ¯ï¼šç”¨äºå¯Œé›†ç‰¹å®šç»†èƒç¾¤ï¼ˆå¦‚è¾èˆç¥ç»åµ´ç»†èƒï¼‰è¿›è¡Œå•ç»†èƒè½¬å½•ç»„å­¦åˆ†æã€‚</p>
<h3>ğŸ§ª åšå®¢æ›´æ–°</h3>
<blockquote>
<p><strong>ä»Šæ—¥ç„¦ç‚¹</strong>ï¼š<br />
ç§‘å­¦å®¶å‘ç°å¤§è„‘å¼€å…³å¯æ¸…é™¤é˜¿å°”èŒ¨æµ·é»˜ç—…æ–‘å—ï¼Œå¹¶å¼€å‘å‡ºèƒ½é€†è½¬æŠ—ç”Ÿç´ è€è¯æ€§å±æœºçš„CRISPRç³»ç»Ÿã€‚</p>
</blockquote>
<p><strong>ä¸»è¦æ–¹å‘</strong>ï¼š<br />
- é˜¿å°”èŒ¨æµ·é»˜ç—…ï¼šç»˜åˆ¶é¦–ä¸ªç»†èƒç±»å‹ç‰¹å¼‚æ€§åŸºå› è°ƒæ§å›¾è°±ï¼Œæ­ç¤ºé©±åŠ¨ç¥ç»é€€åŒ–çš„åŸºå› ç½‘ç»œï¼›å‘ç°æ¸…é™¤æ·€ç²‰æ ·è›‹ç™½æ–‘å—çš„å¤§è„‘å—ä½“ã€‚<br />
- ç™Œç—‡ç ”ç©¶ï¼šå‘ç°ä¸€ç±»æ–°çš„ç™Œç—‡ç‰¹å¼‚æ€§RNAï¼Œå¯å½¢æˆç‹¬ç‰¹çš„åˆ†å­ç­¾åï¼›åˆ©ç”¨å¹²ç»†èƒå¤§è§„æ¨¡ç”Ÿäº§æŠ—è‚¿ç˜¤NKç»†èƒã€‚<br />
- ç©ºé—´è½¬å½•ç»„å­¦ï¼šåˆ©ç”¨DNAæ˜¾å¾®é•œå’ŒRNAæµ‹åºæŠ€æœ¯ï¼Œå®ç°å¤§è§„æ¨¡ä¸‰ç»´åŸºå› è¡¨è¾¾å›¾è°±ç»˜åˆ¶ã€‚</p>
<p><strong>æŠ€æœ¯äº®ç‚¹</strong>ï¼š<br />
- æ•´åˆRNAæµ‹åºä¸å…¨åŸºå› ç»„æ•°æ®ï¼Œæ„å»ºé˜¿å°”èŒ¨æµ·é»˜ç—…ç»†èƒå› æœåŸºå› å›¾è°±ã€‚<br />
- å¼€å‘æ–°å‹CRISPRç³»ç»Ÿï¼Œæœ‰æœ›è§£å†³å…¨çƒæŠ—ç”Ÿç´ è€è¯æ€§å±æœºã€‚</p>
            </div><h2>ğŸ“š åˆ†ç±»æµè§ˆ</h2>
<details>
<summary style="text-align: right; direction: rtl; padding: 10px 15px; background: linear-gradient(135deg, #f8f9fa 0%, #e9ecef 100%); border-right: 4px solid #667eea; font-weight: 600; cursor: pointer; margin: 15px 0; border-radius: 6px;">ğŸ§¬ æ•°æ®å‰æ²¿ (54æ¡)</summary>
<div class="details-content">
<h4>è¯¦ç»†å†…å®¹ï¼ˆå‰10æ¡ï¼‰</h4>
<p><strong>1.</strong> â­ <strong>GSE305116 ç©ºé—´è½¬å½•ç»„å­¦æ­ç¤ºè‚ å‹èƒƒç™Œä¸é…å¯¹çš„æ­£å¸¸èƒƒé»è†œä¹‹é—´ç‹¬ç‰¹çš„å…ç–«å¾®ç¯å¢ƒç‰¹å¾ã€‚</strong><br />
- âœï¸ <strong>ä½œè€…</strong>ï¼šæœªçŸ¥ä½œè€…<br />
- ğŸ·ï¸ <strong>å…³é”®è¯</strong>ï¼šcancerã€immuneã€spatialã€spatial transcriptomicsã€transcriptomicsã€regex:intestin(e|al)<br />
- ğŸ“ <strong>æè¿°</strong>ï¼šContributors : Qingyuan Wang ; Jiajia Shen ; Sheng Yang ; Xiaochun Ping ; Lizong ShenSeries Type : OtherOrganism : Homo sapiensGastric adenocarcinoma, particularly the Lauren intestinal-type GAC (IGAC), leads to significant mortality in China due to the limited effectiveness of current treatments. We performed spatial transcriptomics to profile heterogeneous immune cell clusters in IGAC and validated our findings using scRNA-seq. Our study aims to investigate the mechanisms of immune suppression in IGAC to identify potential targets for enhancing immunotherapy outcomes.<br />
- ğŸ”— <a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE305116" target="_blank" rel="noopener noreferrer">æŸ¥çœ‹åŸæ–‡</a></p>
<p><strong>2.</strong> â­ <strong>GSE298286 åˆ©ç”¨GISå¢å¼ºçš„ç©ºé—´è½¬å½•ç»„å­¦å¯¹åŸå‘æ€§å’Œè½¬ç§»æ€§è‚¿ç˜¤ç»“æ„è¿›è¡Œè®¡ç®—æœºæ¨¡æ‹Ÿé‡å»º</strong><br />
- âœï¸ <strong>ä½œè€…</strong>ï¼šæœªçŸ¥ä½œè€…<br />
- ğŸ·ï¸ <strong>å…³é”®è¯</strong>ï¼štumorã€spatialã€spatial transcriptomicsã€transcriptomics<br />
- ğŸ“ <strong>æè¿°</strong>ï¼šContributors : Jin Young Yoo ; Sabrina Akter ; Qianying Zuo ; Amir Kazemi ; Wenjun Wu ; Mahima Goel ; Audrey Lam ; Debapriya Dutta ; Betsy Barnick ; Melike Pekmezci ; Maria Grosse Perdekamp ; Aiman Soliman ; Zeynep Madak-Erdogan ; Matthew RillorazaSeries Type : Expression profiling by high throughput sequencing ; OtherOrganism : Homo sapiensTumor microenvironment (TME) consists of different cell populations, whose interactions contribute to tumor heterogeneity and therapy response. Spatial transcriptomics (ST) offers valuable insights into spatial complexity and heterogeneity of TME. We established a Python package, Geographic Information System (GIS)-augmented In-Silico Reconstruction of Tumor Architecture (GIS-ROTA), based on application of GIS methods to ST data to examine/explore spatial heterogeneity of co-regulated gene sets, such as pathways and cell types within the TME. In our Visium dataset of primary and metastatic estrogen receptor positive breast tumor samples, GIS-ROTA revealed extensive co-localization of estrogen response with metabolic pathway gene sets and mutual exclusivity with metastasis-related and specific immune-related pathway gene sets. Our findings demonstrate the robustness of GIS-ROTA in quantitating tumor heterogeneity and identifying spatially significant regions while minimizing the subjectivity involved in interpreting the clusters from conventional statistical methods. Thus, GIS-ROTA enables the development of therapeutic strategies that target multiple cell populations.<br />
- ğŸ”— <a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE298286" target="_blank" rel="noopener noreferrer">æŸ¥çœ‹åŸæ–‡</a></p>
<p><strong>3.</strong> â­ <strong>GSE319069 åˆ©ç”¨æŠ—ä½“æ ‡è®°å’Œæµå¼ç»†èƒæœ¯å¯Œé›†ç¥ç»åµ´ç»†èƒï¼Œç”¨äºèœ¥èœ´å•ç»†èƒè½¬å½•ç»„å­¦ç ”ç©¶</strong><br />
- âœï¸ <strong>ä½œè€…</strong>ï¼šæœªçŸ¥ä½œè€…<br />
- ğŸ·ï¸ <strong>å…³é”®è¯</strong>ï¼šantibodyã€single-cellã€transcriptomicsã€enrichment<br />
- ğŸ“ <strong>æè¿°</strong>ï¼šContributors : Robin Pranter ; Cedric Patthey ; Nathalie FeinerSeries Type : Expression profiling by high throughput sequencingOrganism : Podarcis muralisSingle-cell transcriptomic data were generated from embryos of the common wall lizard (Podarcis muralis). Neural crest cells (NCCs) were enriched by fluorescence-activated cell sorting based on HNK-1 antibody staining. The dataset includes two unsorted samples representing all embryonic cells, one leniently sorted sample containing the top 15% of HNK-1â€“positive cells, and two strictly sorted samples containing the top 5% of HNK-1â€“positive cells. Unsorted and leniently sorted samples were generated from pools of three embryos each and sequenced using the 10x Genomics Chromium platform. Strictly sorted samples were generated from a single embryo, split across two plates, and sequenced using the Smart-seq3 protocol. These data enable characterization of NCC transcriptional profiles in a non-model vertebrate species and provide a resource for studying neural crest biology in systems lacking transgenic tools.<br />
- ğŸ”— <a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE319069" target="_blank" rel="noopener noreferrer">æŸ¥çœ‹åŸæ–‡</a></p>
<p><strong>4.</strong> â­ <strong>GSE318783 é€šè¿‡ LHRH-NanoTi é¶å‘é€’é€ TGF-Î² æŠ‘åˆ¶å‰‚å¯é€†è½¬åµå·¢ç™Œä¸­ NAT10/ac4C ä»‹å¯¼çš„é¡ºé“‚è¯±å¯¼çš„å…ç–«æŠ‘åˆ¶æ€§è‚¿ç˜¤å¾®ç¯å¢ƒ [RNA-Seq]</strong><br />
- âœï¸ <strong>ä½œè€…</strong>ï¼šæœªçŸ¥ä½œè€…<br />
- ğŸ·ï¸ <strong>å…³é”®è¯</strong>ï¼štumorã€cancerã€tumor microenvironmentã€RNA-seq<br />
- ğŸ“ <strong>æè¿°</strong>ï¼šContributor : Fei LvSeries Type : Expression profiling by high throughput sequencingOrganism : Mus musculusBackground: Platinum-based chemotherapy for ovarian cancer is frequently compromised by the development of resistance, a process often accompanied by an immunosuppressive tumor microenvironment. The molecular mechanisms linking cisplatin resistance to immune evasion remain poorly understood, hindering the development of effective combination therapies. Results: This study reveals that cisplatin-induced immunosuppression and resistance are driven by a reduction in N-acetyltransferase 10 (NAT10)-mediated N4-acetylcytidine (ac4C) modification, which produces two parts of unfavorable effects: 1) activating the DNA damage repair pathway, thereby confers resistance to cisplatin; 2) enhancing the expression of TGF-Î² via NAT10's interaction with ribosomal proteins RPS3 and RPS6. The elevated TGF-Î² increases the infiltration of myeloid-derived suppressor cells (MDSCs), M2 macrophages, exhausted CD8+ T cells, and regulatory T cells (Tregs) within the tumor microenvironment. To target this pathway, we developed a LHRH receptor-targeted nanodelivery system for a TGF-Î² inhibitor, which synergized with cisplatin to achieve superior antitumor efficacy by effectively reversing the immunosuppressive microenvironment. Conclusions: Our study defines the NAT10/ac4Câ€“TGF-Î² axis as a pivotal mechanism coordinating cisplatin resistance and immunosuppression in ovarian cancer. These findings propose targeted inhibition of TGF-Î² signaling as a promising therapeutic strategy to overcome platinum resistance by revitalizing the antitumor immune response.<br />
- ğŸ”— <a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE318783" target="_blank" rel="noopener noreferrer">æŸ¥çœ‹åŸæ–‡</a></p>
<p><strong>5.</strong> â­ <strong>GSE319533 å…¨åŸºå› ç»„äºšç¡«é…¸æ°¢ç›æµ‹åºæ­ç¤ºç”²é†›è¯±å¯¼çš„é¸¡èƒšè‚è„å’Œéª¨éª¼è‚ŒDNAç”²åŸºåŒ–æ”¹å˜</strong><br />
- âœï¸ <strong>ä½œè€…</strong>ï¼šæœªçŸ¥ä½œè€…<br />
- ğŸ·ï¸ <strong>å…³é”®è¯</strong>ï¼šsequencingã€genomeã€methylation<br />
- ğŸ“ <strong>æè¿°</strong>ï¼šContributors : Mustafa Ã–zdemir ; Saffet Teber ; Ghulam Asghar Sajid ; Selma BÃ¼yÃ¼kkÄ±lÄ±Ã§ Beyzi ; Yunus ArzÄ±k ; Mehmet KÄ±zÄ±laslan ; Servet YalÃ§Ä±n ; Mehmet Ulas CinarSeries Type : Methylation profiling by high throughput sequencingOrganism : Gallus gallusPre-incubation formaldehyde (FA) fumigation of hatching eggs is widely implemented for microbial control, yet its epigenetic consequences in embryonic tissues remain unclear. Here, we profiled the methylome of chicken embryo liver and skeletal muscle following commercial-dose FA fumigation using whole-genome bisulfite sequencing (WGBS). We generated 16 WGBS libraries (per tissue: control n=4; FA n=4), producing ~1.80 billion clean reads with mapping rates of 88.1â€“89.9% and bisulfite conversion efficiencies of ~99.4â€“99.7%. Although global methylation patterns were largely maintained, FA exposure induced widespread locus-specific remodeling dominated by CpG hypomethylation in both tissues. We identified 10,496 DMRs in liver and 10,487 DMRs in muscle, with hypomethylated DMRs comprising 83.4% and 91.2%, respectively. Functional enrichment analyses revealed a tissue-specific adaptive logic. In liver, CG-DMRâ€“associated genes were significantly enriched in Focal adhesion, Tight junction, and core signaling pathways (MAPK, Wnt, Insulin signaling). Notably, hypermethylated genes were enriched for Glycine, serine and threonine metabolism, whereas hypomethylated genes were enriched for Protein processing in endoplasmic reticulum and Autophagy. In the CHG context, hypomethylation preferentially involved ether lipid metabolism, glycerolipid metabolism, and cellâ€“cell adhesion pathways (Adherens junction, Focal adhesion), while CHH-context hypermethylation enriched MAPK and tight junctions. In muscle, CG-DMRs were enriched for â€œhousekeepingâ€ stress-response pathways (Autophagy, Ubiquitin-mediated proteolysis), while a distinct metabolic signature emerged: hypermethylated genes were enriched for PPAR signaling and Biosynthesis of amino acids, whereas hypomethylated genes enriched for Fatty acid metabolism. A decisive metabolic switch was evident in the CHH context, where promoters of Biosynthesis of amino acids were hypermethylated, while catabolic energy pathways (Fatty acid degradation, Valine, leucine and isoleucine degradation, TCA cycle) were hypomethylated. Collectively, these data demonstrate that commercial-dose FA fumigation leaves tissue- and context-specific epigenetic imprints in embryonic liver and skeletal musc...<br />
- ğŸ”— <a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE319533" target="_blank" rel="noopener noreferrer">æŸ¥çœ‹åŸæ–‡</a></p>
<p><strong>6.</strong> â­ <strong>GSE319318 CDKN2A-ARF å¤±æ´»ä¿ƒè¿› PDAC è‚¿ç˜¤å¾®ç¯å¢ƒçš„ p53 éä¾èµ–æ€§é‡å¡‘ [RNA-Seq]</strong><br />
- âœï¸ <strong>ä½œè€…</strong>ï¼šæœªçŸ¥ä½œè€…<br />
- ğŸ·ï¸ <strong>å…³é”®è¯</strong>ï¼štumorã€tumor microenvironmentã€RNA-seq<br />
- ğŸ“ <strong>æè¿°</strong>ï¼šContributors : Brittany M Flowers ; Sofia Ferreira ; Laura D AttardiSeries Type : Expression profiling by high throughput sequencingOrganism : Mus musculusThe CDKN2A locus, which is frequently deleted in pancreatic ductal adenocarcinoma (PDAC), encodes two tumor suppressors, ARF and INK4A, that may influence tumorigenesis through distinct mechanisms. Distinguishing their individual contributions to cancer could help improve the understanding of PDAC pathogenesis and potentially uncover targetable vulnerabilities. Moreover, while ARF is known to enhance p53 function, defining its p53-independent activities could elucidate new processes that drive PDAC development. Here, we sought to understand ARF function in PDAC suppression. Analysis of gene expression and mutational patterns in human PDAC TCGA data indicated that CDKN2AARF and CDKN2AINK4A are commonly both affected by point mutations and/or deletions, suggesting that their combined inactivation contributes to PDAC development. In genetically engineered mouse models (GEMMs), Arf inactivation accelerated KRASG12D-driven PDAC development, both in the presence and absence of Trp53, demonstrating that ARF is a PDAC suppressor and can act in a p53-independent manner. Transcriptomic analyses of PDACs supported a p53-independent role for ARF, with ARF deficiency promoting extracellular matrix, collagen synthesis/assembly, and epithelial-mesenchymal transition gene expression programs. Accordingly, ARF-deficient PDACs displayed extensive remodeling of the tumor microenvironment (TME), associated with collagen deposition, increased tissue stiffness, and higher fibroblast content â€“ hallmarks of aggressive and treatment-resistant PDAC stroma. Together, this study shows how ARF deficiency associated with CDKN2A inactivation sculpts the PDAC TME in a p53-independent fashion. Given the central role of the TME in PDAC progression and therapeutic resistance, these findings may provide insight critical for improving therapeutic interventions for PDAC.<br />
- ğŸ”— <a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE319318" target="_blank" rel="noopener noreferrer">æŸ¥çœ‹åŸæ–‡</a></p>
<p><strong>7.</strong> â­ <strong>GSE318784 é€šè¿‡ LHRH-NanoTi é¶å‘é€’é€ TGF-Î² æŠ‘åˆ¶å‰‚å¯é€†è½¬åµå·¢ç™Œä¸­ NAT10/ac4C ä»‹å¯¼çš„é¡ºé“‚è¯±å¯¼çš„å…ç–«æŠ‘åˆ¶æ€§è‚¿ç˜¤å¾®ç¯å¢ƒ [Ribo-Seq]</strong><br />
- âœï¸ <strong>ä½œè€…</strong>ï¼šæœªçŸ¥ä½œè€…<br />
- ğŸ·ï¸ <strong>å…³é”®è¯</strong>ï¼štumorã€cancerã€tumor microenvironment<br />
- ğŸ“ <strong>æè¿°</strong>ï¼šContributor : Fei LvSeries Type : OtherOrganism : Mus musculusBackground: Platinum-based chemotherapy for ovarian cancer is frequently compromised by the development of resistance, a process often accompanied by an immunosuppressive tumor microenvironment. The molecular mechanisms linking cisplatin resistance to immune evasion remain poorly understood, hindering the development of effective combination therapies. Results: This study reveals that cisplatin-induced immunosuppression and resistance are driven by a reduction in N-acetyltransferase 10 (NAT10)-mediated N4-acetylcytidine (ac4C) modification, which produces two parts of unfavorable effects: 1) activating the DNA damage repair pathway, thereby confers resistance to cisplatin; 2) enhancing the expression of TGF-Î² via NAT10's interaction with ribosomal proteins RPS3 and RPS6. The elevated TGF-Î² increases the infiltration of myeloid-derived suppressor cells (MDSCs), M2 macrophages, exhausted CD8+ T cells, and regulatory T cells (Tregs) within the tumor microenvironment. To target this pathway, we developed a LHRH receptor-targeted nanodelivery system for a TGF-Î² inhibitor, which synergized with cisplatin to achieve superior antitumor efficacy by effectively reversing the immunosuppressive microenvironment. Conclusions: Our study defines the NAT10/ac4Câ€“TGF-Î² axis as a pivotal mechanism coordinating cisplatin resistance and immunosuppression in ovarian cancer. These findings propose targeted inhibition of TGF-Î² signaling as a promising therapeutic strategy to overcome platinum resistance by revitalizing the antitumor immune response.<br />
- ğŸ”— <a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE318784" target="_blank" rel="noopener noreferrer">æŸ¥çœ‹åŸæ–‡</a></p>
<p><strong>8.</strong> â­ <strong>GSE316760 åŸå‘æ€§çš®è‚¤é»‘è‰²ç´ ç˜¤çš„ç©ºé—´è½¬å½•ç»„å­¦</strong><br />
- âœï¸ <strong>ä½œè€…</strong>ï¼šæœªçŸ¥ä½œè€…<br />
- ğŸ·ï¸ <strong>å…³é”®è¯</strong>ï¼šspatialã€spatial transcriptomicsã€transcriptomics<br />
- ğŸ“ <strong>æè¿°</strong>ï¼šContributor : Amaya VirÃ³sSeries Type : OtherOrganism : Homo sapiensWe performed spatial transcriptomics on primary cutaneous melanoma samples to characterise the tumour microenvironment<br />
- ğŸ”— <a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE316760" target="_blank" rel="noopener noreferrer">æŸ¥çœ‹åŸæ–‡</a></p>
<p><strong>9.</strong> â­ <strong>GSE313807 é”™é…ä¿®å¤ç¼ºé™·äº§ç”Ÿçš„èƒè´¨DNAç»“æ„åè°ƒç»“ç›´è‚ ç™Œçš„æŠ—è‚¿ç˜¤å…ç–«</strong><br />
- âœï¸ <strong>ä½œè€…</strong>ï¼šæœªçŸ¥ä½œè€…<br />
- ğŸ·ï¸ <strong>å…³é”®è¯</strong>ï¼štumorã€cancerã€immunity<br />
- ğŸ“ <strong>æè¿°</strong>ï¼šContributors : Kristi Baker ; Shayla MosleySeries Type : Expression profiling by high throughput sequencingOrganism : Mus musculusPatients with the microsatellite instable (MSI) subtype of colorectal cancer (CRC) have better prognosis and immunotherapy response than patients with the chromosomally instable (CIN) subtype due to improved cytotoxic T cell responses. This is in part due to high production of the chemokines CXCL10 and CCL5 from constitutive activation of the cytosolic DNA (cyDNA) sensor cGAS/STING by specific features of MSI cyDNA that lead to more effective cGAS/STING pathway activation. Here, we investigate MSI and CIN cyDNA structure and show that MSI cyDNA is enriched in G-quadruplexes which improve cGAS/STING and CD8+ T cell activation. We also show that micronuclei are less effective at inducing anti-tumor immunity and instead increase Treg activation and IL10 production. Overall, these data highlight the role of specific cyDNA structures in anti-tumor immunity and provide knowledge for improved design of therapeutic DNA-based cGAS/STING agonists to improve the prognosis of poorly immunogenic tumors like CIN CRCs.<br />
- ğŸ”— <a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE313807" target="_blank" rel="noopener noreferrer">æŸ¥çœ‹åŸæ–‡</a></p>
<p><strong>10.</strong> <strong>GSE319696 Setdb1 ä»‹å¯¼çš„ H3K9 ç”²åŸºåŒ–åœ¨éæ´»æ€§ X æŸ“è‰²ä½“ä¸Šå¯Œé›†ï¼Œå¹¶åœ¨å…¶è¡¨è§‚é—ä¼ æ²‰é»˜ä¸­å‘æŒ¥ä½œç”¨ [MEF_RNAseq]</strong><br />
- âœï¸ <strong>ä½œè€…</strong>ï¼šæœªçŸ¥ä½œè€…<br />
- ğŸ·ï¸ <strong>å…³é”®è¯</strong>ï¼šepigeneticã€methylation<br />
- ğŸ“ <strong>æè¿°</strong>ï¼šSeries Type : Expression profiling by high throughput sequencingOrganism : Mus musculusThe presence of histone 3 lysine 9 (H3K9) methylation on the mouse inactive X chromosome has been controversial over the last 15 years, and the functional role of H3K9 methylation in X chromosome inactivation in any species has remained largely unexplored. Here we report the first genomic analysis of H3K9 di- and tri-methylation on the inactive X: we find they are enriched at the intergenic, gene poor regions of the inactive X, interspersed between H3K27 tri-methylation domains found in the gene dense regions. Although H3K9 methylation is predominantly non-genic, we find that depletion of H3K9 methylation via depletion of H3K9 methyltransferase Set domain bifurcated 1 (Setdb1) during the establishment of X inactivation, results in failure of silencing for around 150 genes on the inactive X. By contrast, we find a very minor role for Setdb1-mediated H3K9 methylation once X inactivation is fully established. In addition to failed gene silencing, we observed a specific failure to silence X-linked long-terminal repeat class repetitive element. Here we have shown that H3K9 methylation clearly marks the murine inactive X chromosome. The role of this mark is most apparent during the establishment phase of gene silencing, with a more muted effect on maintenance of the silent state. Based on our data, we hypothesise that Setdb1-mediated H3K9 methylation plays a role in epigenetic silencing of the inactive X via silencing of the repeats, which itself facilitates gene silencing through alterations to the conformation of the whole inactive X chromosome.<br />
- ğŸ”— <a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE319696" target="_blank" rel="noopener noreferrer">æŸ¥çœ‹åŸæ–‡</a></p>
<blockquote>
<p>ğŸ’¡ è¯¥æ¥æºè¿˜æœ‰ 44 æ¡å†…å®¹ï¼Œè¯¦è§ <a href="#æ›´å¤š-æ•°æ®å‰æ²¿">æ–‡æœ«</a></p>
</blockquote>
</div>
</details>

<details>
<summary style="text-align: right; direction: rtl; padding: 10px 15px; background: linear-gradient(135deg, #f8f9fa 0%, #e9ecef 100%); border-right: 4px solid #667eea; font-weight: 600; cursor: pointer; margin: 15px 0; border-radius: 6px;">ğŸ§ª åšå®¢æ›´æ–° (6æ¡)</summary>
<div class="details-content">
<h4>è¯¦ç»†å†…å®¹ï¼ˆå…¨éƒ¨6æ¡ï¼‰</h4>
<p><strong>1.</strong> â­ <strong>CubaseBio ç»“æŸéšç§˜è¿è¥ï¼Œè·å¾— 590 ä¸‡æ¬§å…ƒèèµ„ï¼Œæ—¨åœ¨å®ç°çœŸæ­£çš„ 3D ç©ºé—´è½¬å½•ç»„å­¦è§„æ¨¡åŒ–åº”ç”¨ã€‚</strong><br />
- âœï¸ <strong>ä½œè€…</strong>ï¼šæœªçŸ¥ä½œè€…<br />
- ğŸ·ï¸ <strong>å…³é”®è¯</strong>ï¼šspatialã€spatial transcriptomicsã€transcriptomics<br />
- ğŸ“ <strong>æè¿°</strong>ï¼šCubaseBio secures â‚¬5.9 million to advance 3D spatial transcriptomics powered by DNA microscopy and RNA sequencing, enabling scalable volumetric gene expression mapping for drug discovery and disease research...<br />
- ğŸ”— <a href="https://www.rna-seqblog.com/cubasebio-emerges-from-stealth-to-scale-true-3d-spatial-transcriptomics-with-e5-9m-in-financing/" target="_blank" rel="noopener noreferrer">æŸ¥çœ‹åŸæ–‡</a></p>
<p><strong>2.</strong> <strong>ä¸€é¡¹é‡å¤§ç™Œç—‡çªç ´ï¼šä¸€ä¸ªå¹²ç»†èƒå³å¯ç”Ÿæˆ1400ä¸‡ä¸ªæ€ä¼¤è‚¿ç˜¤çš„NKç»†èƒ</strong><br />
- âœï¸ <strong>ä½œè€…</strong>ï¼šæœªçŸ¥ä½œè€…<br />
- ğŸ·ï¸ <strong>å…³é”®è¯</strong>ï¼štumorã€cancer<br />
- ğŸ“ <strong>æè¿°</strong>ï¼šScientists in China have unveiled a breakthrough way to mass-produce powerful cancer-fighting immune cells in the lab. By engineering early-stage stem cells from cord bloodâ€”rather than trying to modify mature natural killer (NK) cellsâ€”they created a streamlined process that generates enormous numbers of highly potent NK cells, including CAR-equipped versions designed to hunt specific cancers.<br />
- ğŸ”— <a href="https://www.sciencedaily.com/releases/2026/02/260215225600.htm" target="_blank" rel="noopener noreferrer">æŸ¥çœ‹åŸæ–‡</a></p>
<p><strong>3.</strong> <strong>é˜¿å°”èŒ¨æµ·é»˜ç—…é¦–ä¸ªç»†èƒç±»å‹ç‰¹å¼‚æ€§åŸºå› è°ƒæ§å›¾è°±</strong><br />
- âœï¸ <strong>ä½œè€…</strong>ï¼šæœªçŸ¥ä½œè€…<br />
- ğŸ·ï¸ <strong>å…³é”®è¯</strong>ï¼šAlzheimer<br />
- ğŸ“ <strong>æè¿°</strong>ï¼šIntegrating RNA sequencing with whole-genome data, researchers built causal gene maps in Alzheimerâ€™s brain cells, identifying hub genes and rewired networks that may drive neurodegeneration...<br />
- ğŸ”— <a href="https://www.rna-seqblog.com/first-cell-type-specific-gene-regulatory-maps-for-alzheimers-disease/" target="_blank" rel="noopener noreferrer">æŸ¥çœ‹åŸæ–‡</a></p>
<p><strong>4.</strong> <strong>ç¥ç§˜çš„RNAå¼•å¯¼ç§‘å­¦å®¶å‘ç°äº†ç™Œç—‡çš„éšè—å±‚é¢ã€‚</strong><br />
- âœï¸ <strong>ä½œè€…</strong>ï¼šæœªçŸ¥ä½œè€…<br />
- ğŸ·ï¸ <strong>å…³é”®è¯</strong>ï¼šcancer<br />
- ğŸ“ <strong>æè¿°</strong>ï¼šA mysterious RNA found in breast cancer led scientists to uncover an entire hidden class of cancer-specific RNAs across dozens of tumor types. These molecules form unique molecular signatures that identify cancer type and subtype with remarkable accuracy. Some even drive tumor growth and metastasis. Because many are released into the bloodstream, a simple blood test can track how patients respond to treatment and predict survival.<br />
- ğŸ”— <a href="https://www.sciencedaily.com/releases/2026/02/260216084527.htm" target="_blank" rel="noopener noreferrer">æŸ¥çœ‹åŸæ–‡</a></p>
<p><strong>5.</strong> <strong>ç§‘å­¦å®¶å‘ç°èƒ½å¤Ÿæ¸…é™¤é˜¿å°”èŒ¨æµ·é»˜ç—…æ–‘å—çš„å¤§è„‘å¼€å…³</strong><br />
- âœï¸ <strong>ä½œè€…</strong>ï¼šæœªçŸ¥ä½œè€…<br />
- ğŸ·ï¸ <strong>å…³é”®è¯</strong>ï¼šAlzheimer<br />
- ğŸ“ <strong>æè¿°</strong>ï¼šResearchers have identified two brain receptors that help the brain clear away amyloid beta, a hallmark of Alzheimerâ€™s disease. By stimulating these receptors in mice, scientists increased levels of a natural amyloid-breaking enzyme, reduced buildup in the brain, and improved memory-related behavior. Because these receptors are common drug targets, the findings could open the door to affordable pill-based treatments with fewer side effects.<br />
- ğŸ”— <a href="https://www.sciencedaily.com/releases/2026/02/260215225555.htm" target="_blank" rel="noopener noreferrer">æŸ¥çœ‹åŸæ–‡</a></p>
<p><strong>6.</strong> <strong>çªç ´æ€§çš„CRISPRç³»ç»Ÿæœ‰æœ›é€†è½¬æŠ—ç”Ÿç´ è€è¯æ€§å±æœº</strong><br />
- âœï¸ <strong>ä½œè€…</strong>ï¼šæœªçŸ¥ä½œè€…<br />
- ğŸ·ï¸ <strong>å…³é”®è¯</strong>ï¼šresistance<br />
- ğŸ“ <strong>æè¿°</strong>ï¼šAntibiotic resistance is racing toward a global crisis, with â€œsuperbugsâ€ projected to cause over 10 million deaths annually by 2050. Now, scientists at UC San Diego have unveiled a powerful new CRISPR-based tool that doesnâ€™t just fight resistant bacteriaâ€”it can actively strip away their drug resistance. Inspired by gene drives used in insects, the technology spreads a genetic â€œfixâ€ through bacterial populations, even inside stubborn biofilms that shield microbes from antibiotics.<br />
- ğŸ”— <a href="https://www.sciencedaily.com/releases/2026/02/260217005717.htm" target="_blank" rel="noopener noreferrer">æŸ¥çœ‹åŸæ–‡</a></p>
</div>
</details>

<h2>ğŸ“Š å…³é”®è¯ç»Ÿè®¡</h2>
<table class="keywords-table">
<thead>
<tr>
<th>å…³é”®è¯</th>
<th>å‡ºç°æ¬¡æ•°</th>
</tr>
</thead>
<tbody>
<tr>
<td>RNA-seq</td>
<td>13</td>
</tr>
<tr>
<td>cancer</td>
<td>9</td>
</tr>
<tr>
<td>single-cell</td>
<td>8</td>
</tr>
<tr>
<td>tumor</td>
<td>7</td>
</tr>
<tr>
<td>transcriptomics</td>
<td>6</td>
</tr>
<tr>
<td>ChIP-seq</td>
<td>5</td>
</tr>
<tr>
<td>spatial</td>
<td>4</td>
</tr>
<tr>
<td>spatial transcriptomics</td>
<td>4</td>
</tr>
<tr>
<td>tumor microenvironment</td>
<td>4</td>
</tr>
<tr>
<td>methylation</td>
<td>3</td>
</tr>
<tr>
<td>ATAC-seq</td>
<td>3</td>
</tr>
<tr>
<td>sequencing</td>
<td>3</td>
</tr>
<tr>
<td>immune</td>
<td>3</td>
</tr>
<tr>
<td>Alzheimer</td>
<td>2</td>
</tr>
<tr>
<td>epigenetic</td>
<td>2</td>
</tr>
<tr>
<td>genome</td>
<td>2</td>
</tr>
<tr>
<td>carcinoma</td>
<td>2</td>
</tr>
<tr>
<td>transcriptome</td>
<td>2</td>
</tr>
<tr>
<td>metabolic</td>
<td>2</td>
</tr>
<tr>
<td>cardiac</td>
<td>2</td>
</tr>
</tbody>
</table>
<hr />
<h2>ğŸ“ æ›´å¤šå†…å®¹</h2>
<details>
<summary><a name="æ›´å¤š-æ•°æ®å‰æ²¿"></a>ğŸ§¬ æ•°æ®å‰æ²¿ å…¶ä»–å†…å®¹ (44æ¡)</summary>
<div class="details-content">
<ul>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE302204" target="_blank" rel="noopener noreferrer">GSE302204 äººé¼»å’½ç™Œç»†èƒåœ¨ BALF2â€‹â€‹-LR å’Œ BALF2â€‹â€‹-HR è¿‡è¡¨è¾¾ç»„ä¸­çš„ RNA-seq</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE292264" target="_blank" rel="noopener noreferrer">GSE292264 ç¼ºæ°§æ¡ä»¶ä¸‹ Hif1a å’Œ Ahr å¯¹ NK ç»†èƒè½¬å½•ç»„çš„è°ƒæ§</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE318858" target="_blank" rel="noopener noreferrer">GSE318858 CDC14A-KMT5Aä¿¡å·é€šè·¯å¯¹å‘å¿ƒæ€§ä¸ç¦»å¿ƒæ€§å¿ƒè„è‚¥å¤§å¹³è¡¡çš„è°ƒæ§</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE273669" target="_blank" rel="noopener noreferrer">GSE273669 çš®è‚¤ç»†èŒè¯±å¯¼çš„å…±ç”ŸèŒ3Dé»‘è‰²ç´ ç˜¤çš®è‚¤æ¨¡å‹ä¸­çš„åŸºå› è¡¨è¾¾å˜åŒ–</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE319783" target="_blank" rel="noopener noreferrer">GSE319783 æ•´åˆå¤šç»„å­¦åˆ†æå’Œ CRISPR ç­›é€‰é‰´å®šå°é¼ å…ç–«ç³»ç»Ÿä¸­çš„åŠŸèƒ½æ€§éç»å…¸ç¿»è¯‘ä½ç‚¹ [RNA-Seq]</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE316050" target="_blank" rel="noopener noreferrer">GSE316050 é«˜æ•ˆå°åˆ†å­å¯æ§ç¢±åŸºç¼–è¾‘ç”¨äºä½“å†…ç™Œç—‡åŠŸèƒ½åŸºå› ç»„å­¦</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE277536" target="_blank" rel="noopener noreferrer">GSE277536 é«˜å¤æ‚åº¦æ¡å½¢ç ç‹‚çŠ¬ç—…æ¯’ç”¨äºåˆ©ç”¨å•ç»†èƒå’Œå•æ ¸æµ‹åºè¿›è¡Œå¯æ‰©å±•çš„ç”µè·¯æ˜ å°„</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE319313" target="_blank" rel="noopener noreferrer">GSE319313 CDKN2A-ARF å¤±æ´»ä¿ƒè¿› PDAC è‚¿ç˜¤å¾®ç¯å¢ƒçš„ p53 éä¾èµ–æ€§é‡å¡‘ [WES]</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE290140" target="_blank" rel="noopener noreferrer">GSE290140 SET1/COMPASS äºšåŸº RBBP5 åè°ƒå…¨å±€è›‹ç™½è´¨ç¨³æ€å’Œ 12 å°æ—¶æŒ¯è¡å™¨çš„è¡¨è§‚é—ä¼ æ§åˆ¶ï¼Œä»¥ä¿éšœä»£è°¢å’Œç»†èƒç¨³æ€</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE243523" target="_blank" rel="noopener noreferrer">GSE243523 åœ¨é«˜åˆ†è¾¨ç‡å•ç»†èƒ 3D åŸºå› ç»„ä¸­è§‚å¯Ÿåˆ°çš„çªå‡ºè½¬å½•å»¶ä¼¸ç¯ [RNA-seq å’Œ Smart-seq3ã€æ‹“æ‰‘å¼‚æ„é…¶æŠ‘åˆ¶å’Œé»è¿è›‹ç™½è€—ç«­ã€mESC]</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE224898" target="_blank" rel="noopener noreferrer">GSE224898 åœ¨é«˜åˆ†è¾¨ç‡å•ç»†èƒ 3D åŸºå› ç»„ä¸­è§‚å¯Ÿåˆ°çš„çªå‡ºè½¬å½•å»¶ä¼¸ç¯ [Micro-Cã€CUT&amp;TAGã€RNA-Seqã€æ‹“æ‰‘å¼‚æ„é…¶æŠ‘åˆ¶ï¼ˆDMSOã€ETOã€TPTï¼‰ã€GM12878]</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE308091" target="_blank" rel="noopener noreferrer">GSE308091 SWI/SNF çš„ SMARCA4 äºšåŸºå¯é˜²æ­¢ G å››é“¾ä½“å¤„çš„åŸºå› ç»„ä¸ç¨³å®šæ€§</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE300441" target="_blank" rel="noopener noreferrer">GSE300441 ERRÎ±-KDM5C æŠ‘åˆ¶ STING å¢å¼ºå­æ´»æ€§ä»¥è°ƒèŠ‚ä¹³è…ºç™Œè¿›å±•ä¸­çš„ I å‹å¹²æ‰°ç´ ä¿¡å·ä¼ å¯¼</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE298679" target="_blank" rel="noopener noreferrer">GSE298679 Transcriptomic Profiling of Ferroptosis in Enteric Neurons: Bulk RNA-Seq of IM-FEN Cells Treated with Palmitate</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE297210" target="_blank" rel="noopener noreferrer">GSE297210 äº¨å»·é¡¿ç—… DNA ç”²åŸºåŒ–è°±åˆ†ææ­ç¤ºçº¹çŠ¶ä½“ä¸­ä¸ç–¾ç—…ç›¸å…³çš„æ”¹å˜</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE287197" target="_blank" rel="noopener noreferrer">GSE287197 è¯†åˆ«è½¬ç§»è¿›å±•çš„ä»£è°¢æœºåˆ¶</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE286294" target="_blank" rel="noopener noreferrer">GSE286294 Polycombå¤åˆç‰©æŸ“è‰²è´¨ç»“åˆå¤±è¡¡å¯¼è‡´ç¥ç»å‘è‚²éšœç¢[scRNA-Seq]</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE286289" target="_blank" rel="noopener noreferrer">GSE286289 Polycombå¤åˆç‰©æŸ“è‰²è´¨ç»“åˆå¤±è¡¡å¯¼è‡´ç¥ç»å‘è‚²éšœç¢[ChIP-Seq]</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE286288" target="_blank" rel="noopener noreferrer">GSE286288 Polycombå¤åˆç‰©æŸ“è‰²è´¨ç»“åˆå¤±è¡¡å¯¼è‡´ç¥ç»å‘è‚²éšœç¢[ATAC-Seq]</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE286287" target="_blank" rel="noopener noreferrer">GSE286287 Polycombå¤åˆç‰©æŸ“è‰²è´¨ç»“åˆå¤±è¡¡å¯¼è‡´ç¥ç»å‘è‚²éšœç¢[RNA-Seq]</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE279064" target="_blank" rel="noopener noreferrer">GSE279064 LARP6 å½±å“çº¤ç»´åŒ–åŸºå› çš„ mRNA ç¿»è¯‘ [RNA-seq]</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE231768" target="_blank" rel="noopener noreferrer">GSE231768 ç»´ç”Ÿç´ Dç»“åˆè›‹ç™½è¯±å¯¼éª¨éª¼è‚Œèç¼©ï¼Œå¹¶ç‹¬ç«‹äºç»´ç”Ÿç´ Dæ°´å¹³å‚ä¸ç™Œç—‡ç›¸å…³çš„è‚Œè‚‰èç¼©ã€‚</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE319795" target="_blank" rel="noopener noreferrer">GSE319795 è„±ç¢˜é…¶åŸºå› è¡¨è¾¾è°±æ­ç¤ºäº†ç‰›å“ç§ç‰¹å¼‚æ€§ç”²çŠ¶è…ºä»£è°¢å’Œçƒ­åº”æ¿€è€å—æ€§çš„åŸºç¡€</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE313685" target="_blank" rel="noopener noreferrer">GSE313685 å•æ¬¡é™è„‰æ³¨å°„ä¸´åºŠç›¸å…³å‰‚é‡çš„é“å‰‚å¯è¯±å¯¼å¿ƒè¡€ç®¡ä»£è°¢æ€§å¿ƒåŠ›è¡°ç«­æ‚£è€…å‘ç”Ÿå¿ƒè‚Œé“æ­»äº¡</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE302289" target="_blank" rel="noopener noreferrer">GSE302289 miR-146a-5p å’Œ miR-146b-5p é™åˆ¶å¤šå‘æ€§åˆ›ä¼¤æœŸé—´è„‚è‚ªç»„ç»‡ä¸­ IL-1Î² ä»‹å¯¼çš„ç‚ç—‡</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE301368" target="_blank" rel="noopener noreferrer">GSE301368 æ€¥æ€§æ¿€ç´ ä¿¡å·è¯±å¯¼çš„ 3D æŸ“è‰²è´¨ç¯é‡ç»„æ§åˆ¶è„‚è‚ªç»†èƒäº§çƒ­ [ChIP-seq äººç±»]</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE301366" target="_blank" rel="noopener noreferrer">GSE301366 æ€¥æ€§æ¿€ç´ ä¿¡å·è¯±å¯¼çš„ 3D æŸ“è‰²è´¨ç¯é‡ç»„æ§åˆ¶è„‚è‚ªç»†èƒäº§çƒ­ [ChIP-seq å°é¼ ï¼ŒCTCFï¼ŒSMC1ï¼ŒMED1]</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE301359" target="_blank" rel="noopener noreferrer">GSE301359 æ€¥æ€§æ¿€ç´ ä¿¡å·è¯±å¯¼çš„ 3D æŸ“è‰²è´¨ç¯é‡ç»„æ§åˆ¶è„‚è‚ªç»†èƒäº§çƒ­ [RNA-seq äººç±»]</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE261413" target="_blank" rel="noopener noreferrer">GSE261413 æ€¥æ€§æ¿€ç´ ä¿¡å·è¯±å¯¼çš„ 3D æŸ“è‰²è´¨ç¯é‡ç»„æ§åˆ¶è„‚è‚ªç»†èƒäº§çƒ­ [RNA-Seq å°é¼ ]</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE261412" target="_blank" rel="noopener noreferrer">GSE261412 æ€¥æ€§æ¿€ç´ ä¿¡å·è¯±å¯¼çš„ 3D æŸ“è‰²è´¨ç¯é‡ç»„æ§åˆ¶è„‚è‚ªç»†èƒäº§çƒ­ [ChIP-Seq å°é¼ ï¼ŒH3K27acï¼ŒH3K4me3ï¼ŒH2AZ]</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE261410" target="_blank" rel="noopener noreferrer">GSE261410 æ€¥æ€§æ¿€ç´ ä¿¡å·è¯±å¯¼çš„ 3D æŸ“è‰²è´¨ç¯é‡ç»„æ§åˆ¶è„‚è‚ªç»†èƒäº§çƒ­ [ATAC-Seq å°é¼ ]</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE319794" target="_blank" rel="noopener noreferrer">GSE319794 å¯¹æ¥å—æ–°è¾…åŠ© BO-112 å’Œä½åˆ†å‰²æ”¾å°„æ²»ç–—ï¼ˆä¼´æˆ–ä¸ä¼´ nivolumabï¼‰çš„è½¯ç»„ç»‡è‚‰ç˜¤æ‚£è€…çš„è½¯ç»„ç»‡è‚‰ç˜¤è¿›è¡Œæ‰¹é‡ RNA æµ‹åº</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE319779" target="_blank" rel="noopener noreferrer">GSE319779 æ•´åˆå¤šç»„å­¦åˆ†æå’Œ CRISPR ç­›é€‰é‰´å®šå°é¼ å…ç–«ç³»ç»Ÿä¸­çš„åŠŸèƒ½æ€§éç»å…¸ç¿»è¯‘ä½ç‚¹ [Guide-seq]</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE319768" target="_blank" rel="noopener noreferrer">GSE319768 ä¸¤ä¾‹é›†åˆç®¡ç™Œæ‚£è€…çš„è‚¾è„</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE263517" target="_blank" rel="noopener noreferrer">GSE263517 å°é¼ çš®å±‚æ˜Ÿå½¢èƒ¶è´¨ç»†èƒæ ¸è½¬å½•ç»„åˆ†æï¼ˆFmr1 KO å’Œ Smad4 æ¡ä»¶æ€§ KOï¼‰</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE319591" target="_blank" rel="noopener noreferrer">GSE319591 å¼‚è´¨å“ç³»å¤§é¼ å…¨è„‘ç»„ç»‡è½¬å½•ç»„å­¦</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE319577" target="_blank" rel="noopener noreferrer">GSE319577 Single-Cell Profiling of HDAC Inhibitor-Induced EBV Lytic Heterogeneity Defines Abortive and Refractory States in B Lymphoblasts</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE315069" target="_blank" rel="noopener noreferrer">GSE315069 Smad4-p65 ç›¸äº’ä½œç”¨é©±åŠ¨ BMP ä»‹å¯¼çš„æŠ—ç‚ç—‡ç»†èƒæ­»äº¡ä¿æŠ¤ä½œç”¨ [RNA-Seq]</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE315063" target="_blank" rel="noopener noreferrer">GSE315063 Smad4-p65 ç›¸äº’ä½œç”¨é©±åŠ¨ BMP ä»‹å¯¼çš„æŠ—ç‚ç—‡ç»†èƒæ­»äº¡ä¿æŠ¤ä½œç”¨ [ATAC-Seq]</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE315062" target="_blank" rel="noopener noreferrer">GSE315062 Smad4-p65 ç›¸äº’ä½œç”¨é©±åŠ¨ BMP ä»‹å¯¼çš„æŠ—ç‚ç—‡ç»†èƒæ­»äº¡ä¿æŠ¤ä½œç”¨ [ChIP-Seq]</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE288123" target="_blank" rel="noopener noreferrer">GSE288123 è§£æå¤š RRM å†…ä½“ mRNA è½¬è¿è›‹ç™½ Rrm4 çš„ç»“åˆè¡Œä¸º [RNA-seq]</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE243525" target="_blank" rel="noopener noreferrer">GSE243525 åœ¨é«˜åˆ†è¾¨ç‡å•ç»†èƒ3DåŸºå› ç»„ä¸­è§‚å¯Ÿåˆ°çš„çªå‡ºè½¬å½•å»¶ä¼¸ç¯</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE243524" target="_blank" rel="noopener noreferrer">GSE243524 åœ¨é«˜åˆ†è¾¨ç‡å•ç»†èƒ 3D åŸºå› ç»„ä¸­è§‚å¯Ÿåˆ°çš„çªå‡ºè½¬å½•å»¶ä¼¸ç¯ [Micro-C å’Œ CUT&amp;TAGã€Rpb1 è€—ç«­ã€mESC]</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE222243" target="_blank" rel="noopener noreferrer">GSE222243 åœ¨é«˜åˆ†è¾¨ç‡å•ç»†èƒ 3D åŸºå› ç»„ä¸­è§‚å¯Ÿåˆ°çš„çªå‡ºè½¬å½•å»¶ä¼¸ç¯ [Smart-seq2, GM12878]</a></li>
</ul>
</div>
</details>

<hr />
<p><em>ğŸ“… æŠ¥å‘Šç”Ÿæˆæ—¶é—´ï¼š2026-02-18 21:53</em><br />
<em>ğŸ¤– ç”± GitHub Actions è‡ªåŠ¨ç”Ÿæˆ</em></p>
    </div>
</body>
</html>